Stocks Inch Higher after Tuesday Tech Slide
Stock futures inched higher early Wednesday, after investors began the second half with a reduced appetite for technology stocks.Futures for the Dow Jones Industrials edged 17 points to 44,824.Futures for the S&P 500 index surrendered 6.25 points, or 0.1%, to 6,242.50Futures for the NASDAQ dumped 63 points, or 0.3%, to 22,829.75.The information technology sector of the S&P 500 – whose constituents include Nvidia, Palantir and Advanced Micro Devices – lost more than 1% on Tuesday, as did the communications services sector. Instead, investors gravitated toward health care and materials names. Gains in Amgen, Johnson & Johnson and UnitedHealth lifted the 30-stock Dow.Elsewhere, President Donald Trump’s tax-and-spending bill narrowly passed the Senate on Tuesday. The measure will return to the House, where there are still hold-outs among GOP lawmakers.On the economic front Wednesday, investors learned private payrolls fell by 33,000 in June, payrolls processing firm ADP reported Wednesday. The main event in this holiday-shortened week will be June’s big jobs report, due Thursday morning.In Japan, the Nikkei 225 index docked 0.6% Wednesday, while in Hong Kong, the Hang Seng gained 0.6%Oil prices surged 76 cents to $66.21 U.S. a barrel. Gold prices were ahead $9.10 to $3,258.90 U.S. an ounce.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


